This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Paul E. Michaels, PharmD; Robert B. Cameron, MD
Cleveland, Ohio

Arch Intern Med. 1991;151(12):2469.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor. —

We wish to commend Ogbonnaya and Arem¹ for their review on the pathophysiology, diagnosis, and management of diabetic diarrhea that appeared in the February 1990 issue of the ARCHIVES. Some clarifications, however, need to be made regarding the authors' discussion on the role of somatostatin and somatostatin analogues in the management of diabetic diarrhea. Referring to a letter published by Tsai et al,² Ogbonnaya and Arem cite these authors as administering somatostatin in doses of 50 to 75 mg twice a day, while Tsai et al report administering octreotide (not somatostatin) by subcutaneous injection in doses of 50 to 75 µg (ie, micrograms [mcg vs µg], not milligrams) twice a day. A point to be made is that somatostatin and octreotide are separate compounds.³ Somatostatin has been identified as being both a 14- and 28-amino acid peptide (as well as other prosomatostatins) with . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?